Abstract
Background
Clinical judgment of healthcare-associated pneumonia (HCAP) represents a major concern as these fragile patients have an unusual presentation that frequently misleads severity assessment and results in poor clinical outcome. The aim of this study was to evaluate the role of proadrenomedullin (proADM) in predicting disease severity and outcome in HCAP patients in comparison with community-acquired pneumonia (CAP) patients.
Patients and methods
Thirty-one HCAP patients and twenty-five CAP patients were enrolled in this study. Measurement of serum proADM level was performed in the first 24-h of admission. Assessment of severity was carried out using the CURB-65 scoring system. Finally, the outcome of the patients was assessed.
Results
Serum proADM level was higher in HCAP patients than that in CAP patients, this difference was statistically significant. Also, serum proADM level increased significantly with increasing severity of HCAP patients guided by CURB-65, with a cut-off value of more than 1.8 nmol/l, with a sensitivity of 91.7%, a specificity of 95%, a positive predictive value of 91.7%, and a negative predictive value of 95%. However, a higher value (>2.9 nmol/l) was detected in HCAP patients who died, with high sensitivity and negative predictive value (100%) and low specificity (42.3%) and positive predictive value (25%).
Conclusion
The use of proADM as a novel biomarker enhances the performance of the CURB-65 scoring system for risk stratification of HCAP patients. Egypt J Broncho 2014 8:108–114
Article PDF
Similar content being viewed by others
References
Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Healthcare-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy and clinical outcomes. Arch Intern Med 2007; 167:1393–1399.
Micek ST, Kollef KE, Reichley RM, et al. Healthcare-associated pneumonia and community-acquired pneumonia: a single center experience. Antimicrob Agents Chemother 2007; 51:3568–3573.
Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J 2011; 38:878–887.
Polverino E, Cilloniz C, Esquinas C, et al. Healthcare-associated pneumonia (HCAP): clinical features and biomarkers. Am J Respir Crit Care Med 2010; 181:A3212.
Carrabba M, Zarantonello M, Bonara P, et al. Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression. Eur Respir J 2012; 40:1201–1210.
Suberviola B, Castellanos-Ortega A, Llorca J, et al. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012; 142:w13542.
Chaimers JD. ICU admission and severity assessment in community-acquired pneumonia. Crit Care 2009; 13:156.
Michels M, Djamiatun K, Faradz SMH, et al. High plasma mid-regional proadrenomedullin levels in children with severe dengue virus infections. J Clin Virol 2011; 50:8–12.
Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, et al. Adrenomedullin and endothelial barrier function. Thromb Haemost 2007; 98:944–951.
Allaker RP, Grosvenor PW, McAnerney DC, et al. Mechanisms of adrenomedullin antimicrobial action. Peptides 2006; 27:661–666.
Yang S, Zhou M, Fowler DE, et al. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines. Crit Care Med 2002; 30:2729–2735.
Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14:R106.
Bello S, Lasierra AB, Minchole E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39:1144–1155.
Renaud B, Schuetz P, Claessens YE, et al. Proadrenomdullin improves risk of early admission to ICU score for predicting early severe community-acquired pneumonia. Chest 2012; 142:1447–1454.
Polverino E, Torres A. Diagnostic strategies for healthcare-associated pneumonia. Semin Respir Crit Care Med 2009; 30:36–45.
Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB 65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections. Derivation of a clinical algorithm. BMC Infect Dis 2011; 11:112–124.
Porstmann T, Kiessig ST. Enzyme immunoassay techniques: an overview. J Immunol Methods 1992; 150:5–21.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovate therapies in sepsis. Crit Care Med 1992; 20:864–874.
Bernard GAR, Artigas KL, Brigham J, et al. The American European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trials coordination. Am J Respir Crit Care Med 1994; 149:818–824.
Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–250.
Lim WS, Van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–382.
Joong BH, Koh WJ, Yoo H, et al. Performances of prognostic scoring systems in patients with healthcare-associated pneumonia. Clin Infect Dis 2013; 56:625–632. Available at: http://cid.oxfordjournals.org.
Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136:823–831.
Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high pneumonia severity index score community-acquired pneumonia. Am J Emerg Med 2013; 31:215–221. Available at: http://dx.dori.org.
Widmer D, Drozdov D, Rüegger K, et al. Effectiveness of proadrenomedullin enhanced CURB65 score algorithm in patients with community-acquired pneumonia in ‘real life’, an observational quality control survey. J Clin Med 2014; 3:267–279.
Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia free to view. Chest 2005; 128:3854–3862.
Rabello LSC, Pitrowsky MT, Soares M, et al. Novel biomarkers in severe community-acquired pneumonia. Rev Bras Ter Intensiva 2011; 23:499–506.
Christ-Crain M, Morgenthaler NG, Stolz D, et al. (2006): Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTNO4176397]. Available at: http://ccforum.com/content/10/3/R96.
Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional proadrenomedullin as a prognostic maker in sepsis: an observational study. Crit Care 2005; 9:R816–R824.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shaker, A., Gad, D.M., Embarak, S. et al. Role of serum proadrenomedullin in assessment of the severity and outcome of hospitalized healthcare-associated pneumonia patients. Egypt J Bronchol 8, 108–114 (2014). https://doi.org/10.4103/1687-8426.145702
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1687-8426.145702